Results 61 to 70 of about 40,867 (262)
Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
Journal of Bone and Mineral Research, 2021 A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs).
P. Burckhardt +3 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.Magnetic Ion Channel Activation (MICA) enables remote stimulation of mechanosensitive ion channels using functionalised magnetic nanoparticles, enhancing extracellular vesicle (EV) biogenesis is pre‐osteoblasts. MICA desrived EVs exhibit typical nano‐vesicular characteristics but display superior pro‐osteogeneic activity, promoting mesenchymal stem ...
Afeesh Rajan Unnithan +9 more
wiley +1 more source
JBMR PlusBackground Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP). Methods We conducted a 6-month prospective observational study on postmenopausal women with severe OP ...
G. Adami +9 more
semanticscholar +1 more source
What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia [PDF]
, 2016 Zoledronic acid and denosumab were funded by the Australian government for the management of osteoporosis at an equivalent price to alendronate. The price of alendronate has declined by around 65 %, but the price of the other two therapies has remained ...
Karnon, J. +3 more
core +1 more source
Advanced Science, EarlyView.This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen +12 more
wiley +1 more source
Osteoporosis InternationalIn severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab is unclear. We utilised a novel overlapping strategy in three patients with very-high fracture risk despite long-term denosumab which led to greater ...
Shejil Kumar +5 more
semanticscholar +1 more source
Adaptive immunity in cancer immunology and therapeutics. [PDF]
, 2014 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Lockley, M, Spurrell, EL
core +2 more sources
Advanced Science, EarlyView.We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin +10 more
wiley +1 more source
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis [PDF]
Endocrinology and Metabolism, 2015 Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased ...
Yong-Ki Min
doaj +1 more source
Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. [PDF]
, 2020 The surgeon general of the USA defines osteoporosis as "a skeletal disorder characterized by compromised bone strength, predisposing to an increased risk of fracture." Measuring bone strength, Biomechanical Computed Tomography analysis (BCT), namely ...
Bouxsein, ML +6 more
core